EUVIMEDEUVIMED entdecken
Qualitative StudieStudienprotokollOpen Access · CC BY 4.0

Aripiprazole/Sertraline Combination: Clinical and Cost‐Effectiveness in Comparison With Quetiapine for the Treatment of Bipolar Depression (ASCEnD Trial)—Protocol for a Nested Qualitative Study

Isobel Hoppe iD, Stuart Watson iD, Caroline Kemp, Fiona Turnbull, Firoza Davies, John Gibson iD, Lumbini Azim iD, Lauren Wall, Niraj Ahuja iD, Sarah Al-Ashmori iD, Sally Keys, Thomas Kabir iD und 1 weitere

Health Expectations · 2024

DOI: 10.1111/hex.70018 ↗

Kurz gefasst

Qualitative Studie in der Zeitschrift Health Expectations, 2024. Verfasst von Isobel Hoppe und 12 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, Keele University, Newcastle, UK. Hauptthemen laut MEDLINE: Bipolar Disorder, Aripiprazole, Quetiapine Fumarate, Qualitative Research. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: This ASCEnD trial is funded by the National Institute for Health and Care Research (NIHR) (Project Reference Number NIHR132773). CC-G is part-funded by WM ARC..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Bipolar disorder is a recurrent mental health disorder with a prevalence rate of 1.4%. On average, there can be a delay of 9.5 years from the initial presentation of symptoms to a confirmed diagnosis. Individuals living with bipolar disorder have a reduced life expectancy. There is limited evidence regarding the effectiveness of antidepressants in treating bipolar disorder. The ASCEnD clinical trial will test the clinical and cost‐effectiveness of the aripiprazole/sertraline combination in comparison with quetiapine for the treatment of bipolar depression (individuals who suffer from depressive episodes in bipolar disorder) and will include a nested qualitative study.

Methods

The qualitative study will use semi‐structured interviews to explore pilot trial participants' and clinicians' perspectives on recruitment procedures, the acceptability of the intervention, the management of bipolar disorder and attitudes to medication combinations.

Conclusion

Findings will inform recruitment strategies and optimise training for the participating sites in the ASCEnD full trial. They will also help to illuminate the lived experience of people with bipolar disorder and the clinicians who work with people with bipolar disorder. The discussion will explore perspectives on the delay in diagnosis, having a diagnosis, the impact of living with bipolar disorder and attitudes to treatment, including drug combinations. Patient or Public Contribution A Lived Experience Advisory Panel (LEAP) has been convened with the support of the McPin Foundation, which will contribute to the ASCEnD trial and its nested qualitative study to provide input on the design and delivery of the trial and qualitative study, analysis of qualitative data and dissemination of findings.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Bipolar DisorderAripiprazoleQuetiapine FumarateQualitative ResearchCost-Benefit AnalysisAntipsychotic AgentsHumansAntidepressive AgentsInterviews as TopicDrug Therapy, CombinationFemaleMaleAdult

Stichwörter der Autor:innen

bipolar depressionbipolar disorderclinical trialmental healthnested qualitative studypatient and public involvement

Substanzen

AripiprazoleQuetiapine FumarateAntipsychotic AgentsAntidepressive Agents

Autor:innen und Institutionen

  • School of Medicine, Keele University, Newcastle, UK.
  • Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK.
  • Cumbria, Northumberland, Tyne and Wear NHS Trust, Newcastle upon Tyne, UK.
  • McPin Foundation, London, UK.
  • Cumbria, Northumberland, Tyne and Wear NHS Trust, Newcastle University, Newcastle upon Tyne, UK.
  • Regional Affective Disorders Service, Cumbria, Northumberland, Tyne and Wear NHS Trust, Newcastle upon Tyne, UK.

ORCID-Profile: Isobel Hoppe, Stuart Watson, John Gibson, Lumbini Azim, Niraj Ahuja, Sarah Al-Ashmori, Thomas Kabir, Carolyn A Chew-Graham

Förderung

  • This ASCEnD trial is funded by the National Institute for Health and Care Research (NIHR) (Project Reference Number NIHR132773). CC-G is part-funded by WM ARC.

Zitieren

APA

Hoppe, I., Watson, S., Kemp, C., Turnbull, F., Davies, F., Gibson, J., Azim, L., Wall, L., Ahuja, N., Al-Ashmori, S., Keys, S., Kabir, T., & Chew-Graham, C. A. (2024). Aripiprazole/Sertraline Combination: Clinical and Cost‐Effectiveness in Comparison With Quetiapine for the Treatment of Bipolar Depression (ASCEnD Trial)—Protocol for a Nested Qualitative Study. Health Expectations. https://doi.org/10.1111/hex.70018

Vancouver

Hoppe I, Watson S, Kemp C, Turnbull F, Davies F, Gibson J, et al. Aripiprazole/Sertraline Combination: Clinical and Cost‐Effectiveness in Comparison With Quetiapine for the Treatment of Bipolar Depression (ASCEnD Trial)—Protocol for a Nested Qualitative Study. Health Expectations. 2024. doi:10.1111/hex.70018

BibTeX
@article{Hoppe2024,
  author = {Hoppe, Isobel and Watson, Stuart and Kemp, Caroline and Turnbull, Fiona and Davies, Firoza and Gibson, John and Azim, Lumbini and Wall, Lauren and Ahuja, Niraj and Al-Ashmori, Sarah and Keys, Sally and Kabir, Thomas and Chew-Graham, Carolyn A},
  title = {Aripiprazole/Sertraline Combination: Clinical and Cost‐Effectiveness in Comparison With Quetiapine for the Treatment of Bipolar Depression (ASCEnD Trial)—Protocol for a Nested Qualitative Study},
  journal = {Health Expectations},
  year = {2024},
  doi = {10.1111/hex.70018}
}
Kostenlos starten →